Fig. 4From: Survival benefit of ixazomib, lenalidomide and dexamethasone (IRD) over lenalidomide and dexamethasone (Rd) in relapsed and refractory multiple myeloma patients in routine clinical practiceProgression free survival (a) and overall survival (b) by previous autologous stem cell transplantation (ASCT)Back to article page